We found that the expression levels of TLR9 could significantly discriminate the survival of the two GBM subgroups, with a mean PFS of 9 months (median PFS, 11.108 months; 95% CI, 8.843-13.372) for low TLR9 expression group versus mean 6 months (median PFS, 6.958 months; 95% CI, 5.634-8.283) for high TLR9 expression group (p = 0.001) (Fig. 2B and Table 3). This evidence concerns the gene TLR9 and glioblastoma.